PMID- 25231694
OWN - NLM
STAT- MEDLINE
DCOM- 20151027
LR  - 20221207
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 61
IP  - 12
DP  - 2014
TI  - Effect of sitagliptin on glycemic control and beta cell function in Japanese 
      patients given basal-supported oral therapy for type 2 diabetes.
PG  - 1213-20
LID - 10.1507/endocrj.EJ14-0194 [doi]
AB  - We evaluated the effect of sitagliptin on glycemic control, endogenous insulin 
      secretion, and beta cell function in Japanese patients with type 2 diabetes 
      mellitus (T2DM) receiving a combination of oral antidiabetics and basal insulin 
      analog glargine (basal-supported oral therapy [BOT]). Twenty-one patients showing 
      inadequate glycemic control with BOT were given dipeptidylpeptidase-4 inhibitor 
      (DPP-4I) sitagliptin at 50 mg/day for 12 weeks. Clinical markers of glycemic 
      control, HbA1c, glycated albumin (GA), and 1,5-anhydroglucitol (1,5-AG), were 
      measured before and 4 and 12 weeks after the start of sitagliptin. A 2-hour 
      morning meal test was performed upon enrollment and at 12 weeks, and plasma 
      glucose (PG), serum C-peptide, and plasma intact proinsulin (PI) were measured. 
      HbA1c, GA, and 1,5-AG at 4 and 12 weeks were significantly improved over 
      enrollment levels. The area under the PG concentration curve (AUC-PG) during the 
      meal test at 12 weeks was significantly reduced (from 350 +/- 17 mg ･ hr/dL before 
      sitagliptin treatment to 338 +/- 21 mg ･ hr/dL [mean +/- SE], P < 0.05,); the 
      AUC-C-peptide was unchanged (from 3.4 +/- 0.4 ng ･ hr/mL to 3.6 +/- 0.5 ng ･ hr/mL). 
      However, both fasting and 2-hour PI/C-peptide ratios at 12 weeks were 
      significantly decreased (from 13.3 +/- 2.3 to 11.1 +/- 2.0 [P < 0 .05] and from 9.5 +/- 
      1.6 to 5.3 +/- 0.9 [P < 0.01], respectively). Adding sitagliptin to BOT in Japanese 
      T2DM patients appears to improve glycemic control without increasing endogenous 
      insulin secretion and to reduce fasting and 2-hour postprandial PI/C-peptide 
      ratios.
FAU - Asai, Shiko
AU  - Asai S
AD  - Department of Internal Medicine, Division of Metabolism and Endocrinology, St. 
      Marianna University School of Medicine, Kawasaki 216-8511, Japan.
FAU - Ohta, Akio
AU  - Ohta A
FAU - Kato, Hiroyuki
AU  - Kato H
FAU - Sada, Yoshiyuki
AU  - Sada Y
FAU - Nagai, Yoshio
AU  - Nagai Y
FAU - Kondo, Akihiko
AU  - Kondo A
FAU - Sasaoka, Toshiyasu
AU  - Sasaoka T
FAU - Tanaka, Yasushi
AU  - Tanaka Y
LA  - eng
PT  - Journal Article
DEP - 20140917
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Biomarkers)
RN  - 0 (C-Peptide)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
RN  - 0 (Pyrazines)
RN  - 0 (Triazoles)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 9035-68-1 (Proinsulin)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Algorithms
MH  - Biomarkers/blood
MH  - C-Peptide/blood
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/ethnology/physiopathology
MH  - Dipeptidyl-Peptidase IV Inhibitors/administration & dosage/*therapeutic use
MH  - Drug Monitoring
MH  - *Drug Resistance
MH  - Drug Therapy, Combination
MH  - Fatty Acids, Nonesterified/antagonists & inhibitors/blood
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/*prevention & control
MH  - Hypoglycemic Agents/administration & dosage/therapeutic use
MH  - Insulin Glargine
MH  - Insulin, Long-Acting/administration & dosage/therapeutic use
MH  - Insulin-Secreting Cells/*drug effects/metabolism
MH  - Japan
MH  - Male
MH  - Proinsulin/blood/*metabolism
MH  - Pyrazines/administration & dosage/*therapeutic use
MH  - Sitagliptin Phosphate
MH  - Triazoles/administration & dosage/*therapeutic use
EDAT- 2014/09/19 06:00
MHDA- 2015/10/28 06:00
CRDT- 2014/09/19 06:00
PHST- 2014/09/19 06:00 [entrez]
PHST- 2014/09/19 06:00 [pubmed]
PHST- 2015/10/28 06:00 [medline]
AID - DN/JST.JSTAGE/endocrj/EJ14-0194 [pii]
AID - 10.1507/endocrj.EJ14-0194 [doi]
PST - ppublish
SO  - Endocr J. 2014;61(12):1213-20. doi: 10.1507/endocrj.EJ14-0194. Epub 2014 Sep 17.